Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

Citi analyst Joanne Wuensch maintained a Buy rating on Becton Dickinson (BDX – Research Report) today. The company’s shares closed last Friday ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P's 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of 4% in ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

(RTTNews) - Becton, Dickinson and Company (BDX) reported earnings for its first quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and ...

Becton Dickinson plans to break off its biosciences and diagnostic solutions business and focus on the medtech sector. The company said late Wednesday the split could take the form of a sale ...

Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates.

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

Bengaluru: Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its life sciences unit on Wednesday, as the medical device maker aims ...